|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Investments in equity securities | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Receivables from licensing and collaboration agreements | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Investment in nonconsolidated entities | ||||||||||||||||||||
| Equity method investments | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders’ Deficit | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued compensation and benefits | ||||||||||||||||||||
| Accrued research and development liabilities | ||||||||||||||||||||
| Accrued professional services | ||||||||||||||||||||
| Operating lease liabilities, current portion | ||||||||||||||||||||
| Other accrued liabilities | ||||||||||||||||||||
| Accrued professional and other accrued liabilities | ||||||||||||||||||||
| Deferred revenue, current portion | ||||||||||||||||||||
| 2027 Notes, net | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Notes, net | ||||||||||||||||||||
| 2031 Notes | ||||||||||||||||||||
| 2029 Notes | ||||||||||||||||||||
| 2027 Notes | ||||||||||||||||||||
| Notes, net | ||||||||||||||||||||
| 2031 Notes | ||||||||||||||||||||
| 2029 Notes | ||||||||||||||||||||
| 2027 Notes | ||||||||||||||||||||
| 2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes | ||||||||||||||||||||
| 2027 Notes, net | ||||||||||||||||||||
| Term loan, net | ||||||||||||||||||||
| 2029 Notes, net | ||||||||||||||||||||
| 2031 Notes, net | ||||||||||||||||||||
| 2033 Notes, net | ||||||||||||||||||||
| Total 2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes | ||||||||||||||||||||
| Deferred royalty obligations, net | ||||||||||||||||||||
| Operating lease liabilities, net of current portion | ||||||||||||||||||||
| Deferred revenue, net of current portion | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Redeemable convertible noncontrolling interests | ||||||||||||||||||||
| Stockholders’ deficit: | ||||||||||||||||||||
| Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | ||||||||||||||||||||
| Common stock, $0.001 par value; 500,000,000 shares authorized; 198,759,831 shares issued and 192,633,286 shares outstanding as of June 30, 2026, 202,369,129 shares issued and 194,771,957 shares outstanding as of December 31, 2025 | ||||||||||||||||||||
| Treasury stock, at cost; 7,597,172 shares as of June 30, 2025; 6,191,761 shares as of December 31, 2024 | ||||||||||||||||||||
| Treasury stock, at cost; 7,597,172 shares as of June 30, 2026; 7,597,172 shares as of December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total BridgeBio stockholders’ deficit | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||||||
| Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit | ||||||||||||||||||||
Loading...
